Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 189, Issue 8, 2004, Pages 1472-1481

  Blackard, Jason T ^a   Yang, Yijun ^b   Bordoni, Paola ^a   Sherman, Kenneth E ^c   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CLINICAL ARTICLE; CONSENSUS; CONTROLLED STUDY; DATA ANALYSIS; ENTROPY; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC CODE; GENETIC VARIABILITY; GENOMICS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS); VIRAL LOAD;

EID: 2142768221     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/382959     Document Type: Article

References (51)

1. Sherman K, Rouster S, Chung R, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials groups. Clin Infect Dis 2002; 34:831-7.
2. Smith B, Martin J, Ventura S. Births and deaths: preliminary data for July 1997-June 1998. Natl Vital Stat Rep 1999; 47:1-32.
3. Valdez H, Chowdhry T, Assad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001; 32:1487-93.
4. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New Engl J Med 1998; 338:853-60.
5. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
6. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999; 13:539-46.
7. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection. Arch Intern Med 2000; 160:3365-73.
8. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.
9. Chung R, Andersen J, Alston B, et al. A randomized, controlled trial of pegylated interferon α-2a with ribavirin vs. interferon α-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071 [abstract LB15]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:102.
10. Cooper C, Cameron D. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35:873-9.
11. Chung R, Evans S, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C RNA, infrequent liver test flares, and is not impaired by hepatitis C in co-infected subjects. AIDS 2002; 16: 1915-23.
12. Davis G. Hepatitis C virus genotypes and quasispecies. Am J Med 1999; 107:21S-6.
13. Martell M, Esteban J, Quer J, et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 1994; 68:3425-36.
14. Gretch D, Polyak S, Wilson J, Carithers R, Perkins J, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70:7622-31.
15. Sullivan D, Wilson J, Carithers R, Perkins J, Gretch D. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998; 72:10036-43.
16. Brambilla S, Bellati G, Asti M, et al. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology 1998; 27:1678-86.
17. Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 2000; 181:1523-7.
18. Curran R, Jameson C, Craggs J, et al. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 2002; 83:11-23.
19. Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16:619-24.
20. Pawlotsky J. Hepatitis C virus resistance to antiviral therapy. Hepatology 2000; 32:889-96.
21. Ray S, Wang Y, Laeyendecker O, Ticehurst J, Villano S, Thomas D. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999; 73: 2938-46.
22. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-44.
23. Manzin A, Solforosi L, Petrelli E, et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 1998; 72: 6271-6.
24. Sherman K, Andreatta C, O'Brien J, Gutierrez A, Harris R. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 1996; 23:688-94.
25. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol 1997; 26:975-82.
26. Mao Q, Ray S, Laeyendecker Q, et al. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 2001; 75:3259-67.
27. Babik J, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected persons. J Virol 2003; 77:1940-50.
28. Roque-Afonso A, Robain M, Simoneau D, et al. Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. J Infect Dis 2002; 185:728-33.
29. Kolykhalov A, Agapov E, Blight K, Mihalik K, Feinstone S, Rice C. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277:570-4.
30. Thompson J, Higgins D, Gibson T. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
31. Kumar S, Tamura K, Jakobsen I, Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 2001; 17:1244-5.
32. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985; 39:783-91.
33. Wolinksy S, Korber B, Neumann A, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996; 272:537-42.
34. Ragni M, Bontempo F. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180:2027-9.
35. Rutschmann O, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin L. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177:783-5.
36. Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001; 33:1579-85.
37. Neau D, Trimoulet P, Winnock M, et al. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS 2001; 15:1736-8.
38. Mondelli M, Cerino A, Segagni L, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res 2001; 52:153-9.
39. Freeman A, Marinos G, French R, Lloyd A. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001; 79:515-36.
40. Maggi F, Fornai C, Morrica A, et al. Divergent evolution of hepatitis C virus in liver and peripheral blood mononuclear cells of infected patients. J Med Virol 1999; 57:57-63.
41. Roque-Afonso A, Jiang J, Penin F, et al. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol 1999; 73:9213-21.
42. Laskus T, Radkowski M, Wang L, Jang S, Vargas H, Rakela J. Hepatitis C virus quasispecies in patients infected with HIV-1: correlation with extrahepatic replication. Virology 1998; 248:164-71.
43. Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 1999; 29:217-22.
44. Laskus T, Radkowski M, Wilkinson J, Vargas H, Rakela J. The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus. J Infect Dis 2002; 185:417-21.
45. Navas S, Martin J, Quiroga J, Castillo I, Carreno V. Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol 1998; 72:1640-6.
46. Laporte J, Malet I, Andrieu T, et al. Comparative analysis of translation efficiencies of hepatitis C virus 5′ untranslated regions among intraindividual quasispecies present in chronic infection: opposite behaviors depending on cell type. J Virol 2000; 74:10827-33.
47. Laporte J, Bain C, Maurel P, Inchauspe G, Agut H, Cahour A. Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood 2002; 101: 52-7.
48. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75:12047-57.
49. Cline J, Braman J, Hogrefe H. PCR fidelity of Pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res 1996; 24:3546-51.
50. Lauer G, Nguyen T, Day C, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002; 76: 2817-26.
51. Fialaire P, Payan C, Vitour D, et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999; 180:574-5.